Julius Lukas
Overview
Explore the profile of Julius Lukas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millesi M, Pichler L, Denk C, Lukas J, Matula C, Wadiura L
World Neurosurg
. 2021 Jun;
153:e244-e249.
PMID: 34182179
Background: Cavernous venous malformations (CVMs) represent the most common benign intraorbital lesions. Enlarging or symptomatic CVMs (progressive proptosis or visual disturbances) are treated by surgical resection. For this, a variety...
2.
Kiesewetter B, Simonitsch-Klupp I, Mayerhoefer M, Dolak W, Lukas J, Raderer M
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33256131
There is no clear therapeutic algorithm for mucosa-associated lymphoid tissue (MALT) lymphoma beyond Helicobacter pylori eradication and while chemotherapy-based regimens are standard for MALT lymphoma patients in need of systemic...
3.
Kiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer M, Weber M, et al.
Br J Haematol
. 2019 May;
186(3):448-459.
PMID: 31124124
Given the lack of consistent data regarding the clinico-pathological features and clonal lymphomagenesis of patients with mucosa-associated lymphoid tissue (MALT) lymphoma and histological transformation (HT), we have systematically analysed 379...
4.
Mayerhoefer M, Staudenherz A, Kiesewetter B, Weber M, Simonitsch-Klupp I, Gibbs P, et al.
Mol Imaging Biol
. 2019 Mar;
21(6):1192-1199.
PMID: 30847823
Purpose: Standardized uptake values (SUV), total metabolic tumor volumes (TMTV), and total lesion glycolysis (TLG) based on positron emission tomography with 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG/positron emission tomography (PET) are established outcome predictors...
5.
Brammen L, Riss P, Lukas J, Gessl A, Dunkler D, Li S, et al.
Trials
. 2018 Sep;
19(1):495.
PMID: 30219088
Background: Graves' disease (GD) is characterized by thyrotoxicosis and goiter and arises through circulating autoantibodies that bind to, and stimulate, the thyroid hormone receptor (TSHR). A temporal relation between the...
6.
Lagler H, Kiesewetter B, Dolak W, Obermueller M, Simonitsch-Klupp I, Lukas J, et al.
Hematol Oncol
. 2018 Aug;
37(1):22-26.
PMID: 30153341
The macrolide clarithromycin has been reported as active for therapy of mucosa associated lymphoid tissue (MALT) lymphoma. Pharmacokinetic properties, however, require continuous daily intake over a prolonged period of time....
7.
Kiesewetter B, Simonitsch-Klupp I, Kornauth C, Dolak W, Lukas J, Mayerhoefer M, et al.
Hematol Oncol
. 2017 Aug;
36(1):62-67.
PMID: 28833354
Lenalidomide is an active agent for the treatment of MALT lymphoma. Recently, high expression levels of cereblon (CRBN) and MUM1 have been associated with better response rates in multiple myeloma...
8.
Kiesewetter B, Neuper O, Mayerhoefer M, Dolak W, Lukas J, Simonitsch-Klupp I, et al.
Hematol Oncol
. 2017 Jul;
36(1):49-55.
PMID: 28695630
These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses...
9.
Diesner S, Lukas J, Stifter E, Raimann A, Nachbaur E, Eiwegger T, et al.
Klin Padiatr
. 2017 Apr;
229(2):96-99.
PMID: 28444655
No abstract available.
10.
Mayerhoefer M, Karanikas G, Kletter K, Kiesewetter B, Weber M, Rausch I, et al.
Clin Nucl Med
. 2016 Sep;
41(11):837-843.
PMID: 27648705
Purpose: To determine whether interim F-FDG PET or interim diffusion-weighted magnetic resonance imaging (DWI) can predict the end-of-treatment (EOT) outcome after immunotherapy in patients with FDG-avid extranodal marginal zone B-cell...